Anti-Rheumatic Rx
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
COSMOS: Guselkumab in TNF-IR PsA. # OP0230m Coates LC, et al.
C-…
Given its multiple domains, there remains much discussion over the best disease activity scoring method in PsA. The proverbial "holy grail" would be a measure that is quick, intuitive, domain…
3 years 11 months ago
Video: Combination DMARD for Lupus Nephritis: Dr. Kathryn Dao ( @KDAO2011 )
#EULAR2021
https://t.co/RGVZ6jukYy https://t.co/PTjSOfM7YQ
3 years 11 months ago
Video: The PsA SpA Paradox of Choice
Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at the virtual #EULAR2021 meeting.
https://t.co/Yg12SHR1MF https://t.co/UiCYDU5XGc
An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351). Markers of pathways altered in these…
Here are a few notable presentations from Day 3.
BEAT- LUPUS Trial: OP0129 – I would consider this a pilot trial as it only included 52 patients with active SLE, but the gist was that active SLE…
Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of…
The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress,…
Poster Hall